196 related articles for article (PubMed ID: 17116852)
1. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.
Chung NM; Gutierrez M; Turner ML
Arch Dermatol; 2006 Nov; 142(11):1510-1. PubMed ID: 17116852
[No Abstract] [Full Text] [Related]
2. Annular leukocytoclastic vasculitis associated with sorafenib administration.
Najarian DJ; Packianathan V; Zeitouni NC
J Drugs Dermatol; 2010 Jun; 9(6):697-8. PubMed ID: 20645534
[TBL] [Abstract][Full Text] [Related]
3. Hand-foot and stump syndrome to sorafenib.
Lai SE; Kuzel T; Lacouture ME
J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051
[No Abstract] [Full Text] [Related]
4. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
5. Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
Wolber C; Udvardi A; Tatzreiter G; Schneeberger A; Volc-Platzer B
J Dtsch Dermatol Ges; 2009 May; 7(5):449-52. PubMed ID: 19178612
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Diamantis ML; Chon SY
J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
9. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib: atypical cutaneous side effects.
Richetta AG; Maiani E; Carboni V; Carlomagno V; Cimillo M; Mattozzi C; Calvieri S
Eur J Dermatol; 2007; 17(6):549-50. PubMed ID: 17951148
[No Abstract] [Full Text] [Related]
11. [Palmoplantar cutaneous reaction to sorafenib].
Echeverría B; Llombart B; Botella-Estrada R; Guillén C
Actas Dermosifiliogr; 2009 Oct; 100(8):736-7. PubMed ID: 19775561
[No Abstract] [Full Text] [Related]
12. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
13. Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Lopez V; Pinazo I; Marti N; Monteagudo C; Jorda E
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):959-60. PubMed ID: 18785888
[No Abstract] [Full Text] [Related]
14. Paraneoplastic syndrome of non-small cell lung carcinoma: a case with pancytopenia, leukocytoclastic vasculitis, and hypertrophic osteoarthropathy.
Cosar-Alas R; Yurut-Caloglu V; Karagol H; Caloglu M; Yalcin O; Turgut B; Saynak M; Uzal C
Lung Cancer; 2007 Jun; 56(3):455-8. PubMed ID: 17298855
[TBL] [Abstract][Full Text] [Related]
15. Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
Raymond AK; Puri PK; Selim MA; Tyler DS; Nelson KC
Arch Dermatol; 2010 Dec; 146(12):1438-9. PubMed ID: 21173337
[No Abstract] [Full Text] [Related]
16. Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report.
Guillemois S; Patsouris A; Peyraga G; Chassain K; Le Corre Y; Campone M; Augereau P
Clin Breast Cancer; 2018 Oct; 18(5):e755-e758. PubMed ID: 30120047
[No Abstract] [Full Text] [Related]
17. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
[No Abstract] [Full Text] [Related]
18. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
19. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Bianchi G; Loibl S; Zamagni C; Salvagni S; Raab G; Siena S; Laferriere N; Peña C; Lathia C; Bergamini L; Gianni L
Anticancer Drugs; 2009 Aug; 20(7):616-24. PubMed ID: 19739318
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
